Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions

Author(s): Csaba Szabo

Journal Name: Current Vascular Pharmacology

Volume 3 , Issue 3 , 2005

Become EABM
Become Reviewer
Call for Editor


Poly(ADP-ribose) polymerase (PARP) activation plays a role in the pathogenesis of various cardiovascular and inflammatory diseases. Reactive oxygen and nitrogen species induce DNA single strand breaks, which serve as obligatory triggers for the activation of PARP. Pharmacological inhibitors of PARP attenuate ischemic and inflammatory cell and organ injury, and this property of the PARP inhibitors can be exploited for the experimental therapy of disease. As several classes of PARP inhibitors move towards clinical development, or have already entered clinical trials, we expect that in

Keywords: stroke, myocardial infarction, necrosis, apoptosis, blood vessels, inflammation, acute, chronic, drug development, dna repair

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [301 - 303]
Pages: 3
DOI: 10.2174/1570161054368553
Price: $65

Article Metrics

PDF: 3